BEIJING, CHINA, February 7,–Antengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea.
Since established, Antengene Corporation was in a good momentum of development. A few days ago, Antengene Corporation has submitted separately The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea on Jan.16 2018, Feb.1 2018 and Feb.7 2018.
The study title of this application was An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH). Antengene Corporation has received acceptance notice from China on Jan.22 2018. It is expected that Antengene Corporation will receive acceptance notice from Taiwan and Korea after the Lunar New Year in 2018.
Antengene Corporation is a clinical-stage biopharmaceutical company that focuses on introducing cutting-edge treatments, from mid-to-late stage development pipeline to mature brands, to China and other Asian markets. Antengene’s team consists of industry experts with clinical development and regulatory expertise as well as market knowledge and commercial experiences globally, and especially in Asia Pacific. Driven by a larger purpose, Antengene aims at growing into a market leader in the development of innovative therapies to address unmet medical needs globally in the long term.